Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy

What this Trial Is About

Researchers are collecting and studying blood and tissue samples from patients with prostate or bladder/urothelial cancer that has returned near the original tumor or spread to other parts of the body. The study aims to learn more about new biomarkers, drug targets, and resistance to treatments to help improve future cancer care. This observational study is sponsored by the University of Washington and focuses on molecular changes in genitourinary cancers. Participants provide blood and tissue samples that will be analyzed using mutation mapping, DNA sequencing, gene expression microarrays, and gene profiling techniques. The study involves correlative procedures such as cytology specimen collection and laboratory biomarker analysis. Samples may also come from surgical procedures or archival tissue donations. Men and women without cancer may also provide samples if collected during non-research procedures. During the study, researchers will measure DNA sequencing, gene expression profiles, and mutation mapping for up to six years. Additional assessments include examining androgen metabolic enzymes and proteomic profiles. Participants may have tissue biopsies from accessible tumor sites or blood samples taken. The study monitors safety by requiring certain blood counts and coagulation levels. Participation may last several years depending on the follow-up and sample collection schedule.

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer